Amy L. Porter

Amy L. Porter is a business development consultant with over 25 years experience in healthcare.  Amy was Senior Director of Licensing at Pfizer, where she created and led a group responsible for the identification and technical due diligence of licensing opportunities, as well as for representing the global R&D function in licensing negotiations. To leverage Pfizer’s expertise in both R&D and marketing, Amy formed global, cross-functional teams across all therapeutic areas to evaluate drugs in development worldwide. She also conceived of and led the development of a proprietary and comprehensive drug database to maximize the availability and sharing of information. Both her database and the multi-disciplinary teams have proven to be essential for identifying, evaluating, and closing licensing deals, and are still employed globally at Pfizer today.

While at Pfizer, Amy also developed performance metrics and a variety of scholarship tools that enabled her licensing group to become more broadly involved in portfolio assessment and strategic innovation. Amy served as an advisor to Senior Management for the acquisitions of both Warner- Lambert and Pharmacia, as well as for ongoing internal portfolio planning activities across all therapeutic areas.

Prior to joining Pfizer, Amy was Director of Business Development at BASF Bioresearch, where she led international negotiations for both in-licensing and out-licensing opportunities. Amy was also a co-founder and Director of Technology Management & Licensing at ARIAD Pharmaceuticals, where she led licensing negotiations, wrote business plans, and contributed to raising capital and strategic planning.

Prior to her transition to industry, Amy gained broad experience in intellectual property management and contract negotiations at the Technology Licensing Offices of Stanford University and M.I.T. She worked closely with professors, entrepreneurs, and venture capitalists in identifying founding technologies for a number of start-up companies, as well as licensing enabling technologies to large corporations. Her areas of focus included medicine, biotechnology, medical devices, polymer science, chemical engineering, and materials science.